Quoin Pharmaceuticals (NASDAQ:QNRX) Posts Quarterly Earnings Results, Misses Estimates By $0.35 EPS

Posted by Linda Flegge on Nov 8th, 2025

Quoin Pharmaceuticals (NASDAQ:QNRX – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($6.71) EPS for the quarter, missing the consensus estimate of ($6.36) by ($0.35), Zacks reports.

Quoin Pharmaceuticals Price Performance

Quoin Pharmaceuticals stock traded up $0.44 during midday trading on Friday, hitting $9.01. 44,442 shares of the stock were exchanged, compared to its average volume of 222,841. The company has a 50 day moving average price of $9.85 and a two-hundred day moving average price of $8.61. The firm has a market cap of $5.30 million, a P/E ratio of -0.22 and a beta of 1.72. Quoin Pharmaceuticals has a 1 year low of $5.01 and a 1 year high of $48.30.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research report on Wednesday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Get Our Latest Report on QNRX

Insider Transactions at Quoin Pharmaceuticals

In related news, Director Dennis Langer acquired 15,152 shares of Quoin Pharmaceuticals stock in a transaction on Tuesday, October 14th. The shares were purchased at an average cost of $8.49 per share, for a total transaction of $128,640.48. Following the purchase, the director directly owned 15,153 shares of the company’s stock, valued at $128,648.97. The trade was a 1,515,200.00% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 13.46% of the stock is owned by corporate insiders.

Quoin Pharmaceuticals Company Profile

(Get Free Report)

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.